Human embryonic stem cells (hESC) are pluripotent cells derived from the blastocyst inner cell mass, a 5-6 day-old embryo. In order to obtain these cells, that early human embryo needs to be destroyed, causing objective ethical problems.
The first hESC lines were produced by Thomson et al in 1998 (1) . Since, they have been widely used for experimental purposes; however, their therapeutic use is much more reduced.
In fact, ClinicalTrials.org states that 144,300 clinical trials have been carried out worldwide (2) .
4451 of those, with adult stem cells, and only 15 with hESC (Table 1) .
In order to ascertain that those 15 clinical trials had actually used hESC with therapeutic purposes, we analyzed them to see whether there was objective data.
We previously established that the aim of trials 10 and 12 was to produce induced pluripotent stem cells (iPS) or to assess their action. In trial 13, they used autologous mesenchymal cells; in trial 14, umbilical cord cells and, in trial 15, only adult stem cells circulating levels were assessed.
In trials 1 and 9, hESC were used, however in trial 1 there had not been patient recruitment yet. In trial 2, the first data would not be obtained until February 2016; in trial 3 until January 2014 and, in trial 8, until August 2014. Clinical trials 4, 6 and 9 were aimed at improving the obtaining technique of the embryonic stem cells lines.
Only trials 5 and 7 had the objective to assess the hESC therapeutic use and provided a specific result.
Preliminary data of these two trials has been published in The Lancet (3). In trial 5 (NCT01345006), they assessed the safety and tolerability of retinal transplantation of hESCderived retinal pigmented epithelium (hESCP-RPE) on a patient with Stargardt macular dystrophy and on a patient with dry age-related macular degeneration, in trial 7 (NCT 01344993). The visual acuity improved from hand motions to 20/800 in the eye 3 study of the patient with Stargardt macular dystrophy and vision also seemed to improve in the patient with dry age-related macular degeneration (from 21 ETDRS letters to 28).
Thus, can anything be concluded from the use of hESC for therapeutic purposes only from the data of these two patients? In our opinion, there is no medical evidence that justifies their use. 
